Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281085 | 0.85 | TDP1 (0.71) | TDP1MEN1KMT2ACYP1A2 | |
| SCHEMBL7560719 | 0.84 | SIGMAR1 (0.40) | TDP1CYP3A4IDO1APPSIGMAR1 | |
| SCHEMBL7561947 | 0.82 | THRA (0.41) | TDP1CYP3A4IDO1APPSIGMAR1 | |
| SCHEMBL2355588 | 0.82 | CYP3A4 (0.50) | CYP3A4IDO1APPCYP1A2CYP2D6 | |
| SCHEMBL6510298 | 0.82 | CYP3A4 (0.50) | CYP3A4IDO1APPCYP1A2CYP2D6 | |
| SCHEMBL30932186 | 0.82 | TDP1 (0.67) | TDP1MEN1KMT2ACYP1A2 | |
| SCHEMBL7560868 | 0.80 | THRA (0.43) | TDP1CYP3A4IDO1SIGMAR1 | |
| SCHEMBL7561616 | 0.80 | THRA (0.43) | TDP1CYP3A4IDO1SIGMAR1 | |
| SCHEMBL8070936 | 0.80 | THRA (0.43) | TDP1CYP3A4IDO1SIGMAR1 | |
| SCHEMBL7562178 | 0.80 | THRA (0.43) | TDP1CYP3A4IDO1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102695741-A | Norbornene-type polymers having quaternary ammonium functionality | PROMERUS LLC | 2012-09-26 | — | — | CN | disclosed |
| US-8022235-B2 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | CELLECTAR, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7893286-B2 | Method for the synthesis of phospholipid ethers | CELLECTAR, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090018357-A1 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | CELL ACQUISITION CORP. | 2009-01-15 | — | — | US | disclosed |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | CELL ACQUISITION CORP. | 2008-12-18 | — | — | US | disclosed |
| WO-2008150439-A1 | COMPOSITIONS OF PHOSPHOLIPID ETHER BORONIC ACIDS AND ESTERS AND METHODS FOR THEIR SYNTHESIS AND USE | CELLECTAR, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2003082301-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| CN-1121376-C | Substituted 4-diarylbutanoic or 5-diarylpentanoic acids and derivatives thereof as matrix metalloproteinase inhibitors | BAYER AG (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| CN-1163604-A | Substituted 4-diarylbutanoic or 5-diarylpentanoic acids and derivatives thereof as matrix metalloproteinase inhibitors | BAYER AG (US) | 1997-10-29 | — | — | CN | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| US-4633026-A | DEHYDROHALOGENATION OF RING-HALOGENATED ALPHA- OR BETA-BROMOETHYL BENZENES WITH STRONG BASE, POLYOXYETHYLENE GLYCOL CATALYST, AMINE POLYMERIZATION INHIBITOR | ETHYL CORPORATION (US) | 1986-12-30 | — | — | US | disclosed |
| US-4292453-A | REACTION OF A HALO DERIVATIVE OF BETA-BROMOETHYLBENZENE WITH AQUEOUS ALKALI AND A QUATERNARY PHASE TRANSFER CATALYST | MAKHTESHIM CHEMICAL WORKS LTD. (IL) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018357-A1 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | PHOSPHO1, PEBP1, SGMS1 | TDP1 1387/4885CYP3A4 3964/4885IDO1 4806/4885 |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | PHOSPHO1, PLEC, PLA2G2C | TDP1 2013/4885CYP3A4 1112/4885IDO1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.